First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Clinical Cancer Research|2014Cited by 47
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trialJames Spicer, Sophia N. Karagiannis, Paul S. Jones et al.|Nature Communications|2023Cited by 35
Immune checkpoint inhibitor induced large vessel vasculitisDaisy Henderson, Debra H. Josephs, Gelareh Eslamian et al.|BMJ Case Reports|2020Cited by 18
Republished: Immune checkpoint inhibitor induced large vessel vasculitisDaisy Henderson, Debra H. Josephs, Gelareh Eslamian et al.|Drug and Therapeutics Bulletin|2020Cited by 2
Data from First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Unknown|2023Cited by 0